| BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells ED Lagadinou, A Sach, K Callahan, RM Rossi, SJ Neering, ... Cell stem cell 12 (3), 329-341, 2013 | 1516 | 2013 |
| Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age EB Walter, KR Talaat, C Sabharwal, A Gurtman, S Lockhart, GC Paulsen, ... New England Journal of Medicine 386 (1), 35-46, 2022 | 728 | 2022 |
| SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3 AR Falsey, RW Frenck Jr, EE Walsh, N Kitchin, J Absalon, A Gurtman, ... New England Journal of Medicine 385 (17), 1627-1629, 2021 | 426 | 2021 |
| Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine ED Moreira Jr, N Kitchin, X Xu, SS Dychter, S Lockhart, A Gurtman, ... New England journal of medicine 386 (20), 1910-1921, 2022 | 384 | 2022 |
| First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors TA Yap, DSP Tan, A Terbuch, R Caldwell, C Guo, BC Goh, V Heong, ... Cancer discovery 11 (1), 80-91, 2021 | 246 | 2021 |
| Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells S Pei, M Minhajuddin, KP Callahan, M Balys, JM Ashton, SJ Neering, ... Journal of Biological Chemistry 288 (47), 33542-33558, 2013 | 240 | 2013 |
| Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study J Li, A Hui, X Zhang, Y Yang, R Tang, H Ye, R Ji, M Lin, Z Zhu, Ö Türeci, ... Nature medicine 27 (6), 1062-1070, 2021 | 144 | 2021 |
| Preclinical characterization and phase I trial results of a bispecific antibody targeting PD-L1 and 4-1BB (GEN1046) in patients with advanced refractory solid tumors A Muik, E Garralda, I Altintas, F Gieseke, R Geva, E Ben-Ami, ... Cancer discovery 12 (5), 1248-1265, 2022 | 117 | 2022 |
| Clinical development and approval of COVID-19 vaccines U Kalinke, DH Barouch, R Rizzi, E Lagkadinou, Ö Türeci, S Pather, ... Expert review of vaccines 21 (5), 609-619, 2022 | 94 | 2022 |
| Phase I assessment of safety and therapeutic activity of BAY1436032 in patients with IDH1-mutant solid tumors A Wick, O Bähr, M Schuler, K Rohrberg, SP Chawla, F Janku, D Schiff, ... Clinical cancer research 27 (10), 2723-2733, 2021 | 66 | 2021 |
| Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial SJ Thomas, JL Perez, SP Lockhart, S Hariharan, N Kitchin, R Bailey, ... Vaccine 40 (10), 1483-1492, 2022 | 64 | 2022 |
| Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results M Heuser, N Palmisiano, I Mantzaris, A Mims, C DiNardo, LR Silverman, ... Leukemia 34 (11), 2903-2913, 2020 | 62 | 2020 |
| Disease-related anemia in chronic lymphocytic leukemia is not due to intrinsic defects of erythroid precursors: a possible pathogenetic role for tumor necrosis factor-alpha OA Tsopra, PG Ziros, ED Lagadinou, A Symeonidis, ... Acta haematologica 121 (4), 187-195, 2009 | 59 | 2009 |
| Challenges in treating older patients with acute myeloid leukemia LD Eleni, ZC Nicholas, S Alexandros Journal of oncology 2010 (1), 943823, 2010 | 56 | 2010 |
| c-Jun N-terminal kinase activation failure is a new mechanism of anthracycline resistance in acute myeloid leukemia ED Lagadinou, PG Ziros, OA Tsopra, K Dimas, D Kokkinou, ... Leukemia 22 (10), 1899-1908, 2008 | 47 | 2008 |
| Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity KP Callahan, M Minhajuddin, C Corbett, ED Lagadinou, RM Rossi, ... Leukemia 28 (10), 1960-1968, 2014 | 46 | 2014 |
| First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JS De Bono, DSP Tan, R Caldwell, A Terbuch, BC Goh, V Heong, ... Journal of Clinical Oncology 37 (15_suppl), 3007-3007, 2019 | 42 | 2019 |
| Alloreactive microenvironment after human hematopoietic cell transplantation induces genomic alterations in epithelium through an ROS-mediated mechanism: in vivo and in vitro … M Themeli, L Petrikkos, M Waterhouse, H Bertz, E Lagadinou, N Zoumbos, ... Leukemia 24 (3), 536-543, 2010 | 39 | 2010 |
| Expression patterns of leptin receptor (OB-R) isoforms and direct in vitro effects of recombinant leptin on OB-R, leptin expression and cytokine secretion by human … A Mouzaki, I Panagoulias, Z Dervilli, V Zolota, P Spadidea, M Rodi, ... Cytokine 48 (3), 203-211, 2009 | 36 | 2009 |
| A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults M Haranaka, J Baber, Y Ogama, M Yamaji, M Aizawa, O Kogawara, ... Nature Communications 12 (1), 7105, 2021 | 33 | 2021 |
